Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer

Published:2023-10 Issue: Volume: Page:
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Edwards Donna M.^ORCID,Sankar Kamya,Alseri Aaren,Jiang Ralph,Schipper Matthew,Miller Sean,Dess Kathryn,Strohbehn Garth W.,Elliott David A.,Moghanaki Drew,Ramnath Nithya,Green Michael D.,Bryant Alex K.^ORCID

Funder

National Cancer Institute

U.S. Department of Veterans Affairs

LUNGevity Foundation

Melanoma Research Alliance

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference38 articles.

1. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

2. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

3. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Spigel;J Clin Oncol,2022

4. Radiation pneumonitis: Old problem, new tricks;Jain;Cancers (Basel),2018

5. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis;Giobbie-Hurder;JAMA Oncol,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. OncoFlash – Research updates in a Flash! January 24 edition;Clinical Oncology;2024-01

2. Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer;Frontiers in Immunology;2023-11-24